Exelixis | EXEL - Pasivo Circulante





Pasivo Circulante Cambio Fecha
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Akebia Therapeutics USD 173.88M 10.95M 2026-03
Amgen USD 24.96B 534M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
Bayer EUR 33.46B 875M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Cytokinetics USD 199.18M 3.27M 2026-03
Eisai JPY 340.25B 47.42B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.36M 451K 2026-03
Exelixis USD 370.98M 34.67M 2026-03
Genmab DKK 1.43B 686M 2025-12
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.49B 25.52M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
MacroGenics USD 95.94M 52.82M 2026-03
Merck USD 26.94B 1.38B 2026-03
Moderna USD 2.4B 408M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Pfizer USD 34.35B 2.64B 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sanofi EUR 28.35B 9.32B 2025-12
Takeda JPY 2.43T 180.65B 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Xencor USD 73.46M 22.45M 2026-03